Skip to main content

Advertisement

SpringerLink
Log in

Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma. Previously untreated patients with histologically or cytologically confirmed squamous cell carcinoma were randomly assigned into two groups (each had 45 patients): cisplatin + 5-fluorouracil + radiotherapy (PF) group and cisplatin + docetaxel + radiotherapy (DP) group. All patients received radiotherapy of 50.4 Gy (28 fractions of 1.8 Gy) over 5 weeks (5 fractions a week). Chemotherapy for PF group comprises 5-fluorouracil at days 1–4 (250 mg/m2/day) and cisplatin (75 mg/m2) at day 1 of every 28-day cycle; full treatment course included 4 cycles. Chemotherapy for DP group comprises docetaxel (75 mg/m2) and cisplatin (75 mg/m2) at day 1 of every 28-day cycle; full treatment course included 4 cycles. Response, survival, progression and toxicity of both regimens were studied. Overall response rate (ORR) was 53.3 % for PF group and 73.3 % for DP group. Median overall survival (OS) time was 22.3 months for PF group and 43.2 group months for DP: Patients of DP group had a significant longer overall median survival time (P < 0.05). Toxicity was acceptable; patients of PF group and patients of DP group did not showed significant difference in serious haematological event incidence (24.4 vs. 35.6 %, P > 0.05). ORR and OS favour DP over PF in the treatment of patients with unresectable local advanced oesophageal squamous cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol. 2009;92:276–90.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  3. Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut. 1994;35:941–5.

    Article  PubMed  CAS  Google Scholar 

  4. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.

    PubMed  CAS  Google Scholar 

  5. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.

    Article  PubMed  CAS  Google Scholar 

  6. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85- 01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–7.

    Article  PubMed  CAS  Google Scholar 

  7. Stuschke M, Stahl M, Wilke H, Walz M, Oldenburg A, Stuben G, Seeber S, Sack H. Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus. Am J Clin Oncol. 2000;23:233–8.

    Article  PubMed  CAS  Google Scholar 

  8. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004;22:45–52.

    Article  PubMed  CAS  Google Scholar 

  9. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.

    Article  PubMed  CAS  Google Scholar 

  10. Hsu FM, Lin CC, Lee JM, Chang YL, Hsu CH, Tsai YC, Lee YC, Cheng JC. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective nonrandomized study. J Surg Oncol. 2008;98:34–41.

    Article  PubMed  Google Scholar 

  11. Chiarion-Sileni V, Corti L, Ruol A, Innocente R, Boso C, Del Bianco P, Pigozzo J, Mazzarotto R, Tomassi O, Ancona E. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced esophageal cancer. Br J Cancer. 2007;96:432–8.

    Article  PubMed  CAS  Google Scholar 

  12. Choy H. Combining taxanes with radiation for solid tumors. Int J Cancer. 2000;90:113–27.

    Article  PubMed  CAS  Google Scholar 

  13. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;3:2431–8.

    PubMed  CAS  Google Scholar 

  14. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1999;16:159–64.

    Google Scholar 

  15. Hihara J, Yoshida K, Hamai, Emi M, Yamaguchi Y, Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res. 2007;27:2597–604.

    PubMed  CAS  Google Scholar 

  16. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:533–7.

    PubMed  CAS  Google Scholar 

  17. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–8.

    PubMed  CAS  Google Scholar 

  18. Khokhar NZ, Jiang Y, Benson AB 3rd, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2011;4(3):96–105.

    PubMed  Google Scholar 

  19. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F, Swiss Group for Clinical Cancer Research. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin- 5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2007;25:3217–23.

    Article  PubMed  CAS  Google Scholar 

  20. Day FL, Leong L, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Lulio J, Matera A, Michael M. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2011;104:265–71.

    Article  PubMed  CAS  Google Scholar 

  21. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. NT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined modality therapy for esophageal cancer: High2dose versus standard dose radiation therapy. J Clin Oncol. 2002;20:1167–74.

    Article  PubMed  CAS  Google Scholar 

  22. Kelsey CR, Chino JP, Willett CG, Clough RW, Hurwitz HI, Morse MA, Bendell JC, D’Amico TA, Czito BG. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;69:770–6.

    Article  PubMed  CAS  Google Scholar 

  23. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B. Phase II study of preoperative paclitaxel/cisp latin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;67:397–404.

    Article  PubMed  CAS  Google Scholar 

  24. Laack E, Andritzky B, Durk H, Burkholder I, Edler L, Schuch G, Boeters I, Gorn M, Lipp R, Horst H, Popp J, Hossfeld DK. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie. 2005;28:647–50.

    Article  PubMed  CAS  Google Scholar 

  25. Ilson DH, Bains M, Ginsberg RJ, Kelsen DP. Neoadjuvant therapy of esophageal cancer. Surg Oncol Clin N Am. 1997;6:723–40.

    PubMed  CAS  Google Scholar 

  26. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360–7.

    Article  PubMed  CAS  Google Scholar 

  27. Chen E, Liu M, Hu Y, Cai L, Li Q, Liu H. A case-control study on unresectable esophageal carcinoma patients with radiochemotherapy or radiotherapy. Chin J Radiat Oncol. 2007;16(6):416–9.

    CAS  Google Scholar 

  28. Zhang P, Xie C, Wu S. Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal. Chin J Oncol. 2007;29(10):773–7.

    CAS  Google Scholar 

Download references

Acknowledgments

Tingrong Zhang declare that he have no conflict of interest in any form from a commercial party related directly or indirectly to the subject of this manuscript or any of the authors must be acknowledged.

Author information

Authors and Affiliations

  1. Department of Oncology, The Affiliated Jiangyin People’s Hospital, School of Medicine, Southeast University, Jiangyin, 214400, China

    Tao Zhao & Tingrong Zhang

  2. Department of Oncology, Fudan University Cancer Center, Shanghai, 200032, China

    Hao Chen

Authors
  1. Tao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tingrong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tingrong Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, T., Chen, H. & Zhang, T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol 29, 3017–3023 (2012). https://doi.org/10.1007/s12032-012-0228-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0228-6

Keywords

Search

Navigation